Cargando…

Adjuvant chemotherapy guidance for pT1–3N0–1 breast cancer patients with HR(+), HER2(−) subtype: a cohort study based on the SEER database

BACKGROUND: Although the results of gene testing can guide early breast cancer patients with hormone receptor (HR)(+), human epidermal growth factor receptor 2 (HER2)(−) to decide whether they need chemotherapy (CHT), there are still many patients worldwide whose problems cannot be resolved by genet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wen, Nan, Qiu, Juanjuan, Xu, Li, Wang, Yu, Zhang, Jia, Xie, Yanyan, Lv, Qing, Du, Zhenggui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756223/ https://www.ncbi.nlm.nih.gov/pubmed/35071473 http://dx.doi.org/10.21037/atm-21-5937

Ejemplares similares

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database
por: Hu, Guangfu, et al.
Publicado: (2020)

Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort
por: Shen, Kaiwen, et al.
Publicado: (2022)

Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups With HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database
por: Cheng, Ran, et al.
Publicado: (2020)

The Role of Adjuvant Chemotherapy in Metaplastic Breast Carcinoma: A Competing Risk Analysis of the SEER Database
por: Lan, Tian, et al.
Publicado: (2021)

Exploration of prognostic factors and the value of adjuvant chemotherapy in T1a,bN0M0 triple-negative breast cancer: a prospective cohort study based on the SEER database
por: Wu, Junzhao, et al.
Publicado: (2022)

Survival benefit of perioperative chemotherapy for T1–3N0M0 stage esophageal cancer: a SEER database analysis
por: Shao, Yue, et al.
Publicado: (2021)

RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients
por: Wang, Haibo, et al.
Publicado: (2022)

Is adjuvant chemotherapy necessary in pT1N1 gastric cancer?
por: Shin, Hyun Beak, et al.
Publicado: (2017)

Evaluation of whether adjuvant chemotherapy can be safely omitted for older female patients with ER-positive, HER2-negative N1 breast cancer: a study based on the SEER database
por: Lv, Minhao, et al.
Publicado: (2021)

Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling
por: Xylinas, E, et al.
Publicado: (2012)

Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study
por: Gori, Stefania, et al.
Publicado: (2012)

Is Adjuvant Chemotherapy Beneficial to All Patients With pT3N0M0 Stage Gastric Cancer?
por: Huang, Jiao-Bao, et al.
Publicado: (2021)

Effect of adjuvant chemotherapy on the survival outcomes of elderly breast cancer: A retrospective cohort study based on SEER database
por: Wu, Yunhao, et al.
Publicado: (2022)

Benefits of Adjuvant Chemotherapy Differ by Menopausal Status in Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Recurrence Score
por: Jacobson, Anne
Publicado: (2022)

Adjuvant Chemotherapy in pT2N0M0 Gastric Cancer: Findings From a Retrospective Study
por: Mei, Yu, et al.
Publicado: (2022)

The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer
por: Gori, Stefania, et al.
Publicado: (2015)

Adjuvant therapy for HER2 positive pT1a-b pN0 breast cancer: A single center cohort study
por: Yang, Xuan, et al.
Publicado: (2022)

Adjuvant chemoradiotherapy vs chemotherapy for resectable biliary tract cancer: a propensity score matching analysis based on the SEER database
por: Zhu, Yueting, et al.
Publicado: (2023)

Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program
por: Li, Juanjuan, et al.
Publicado: (2017)

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
por: Ascione, Liliana, et al.
Publicado: (2022)

For or against Adjuvant Trastuzumab for pT1a-bN0M0 Breast Cancer Patients with HER2-Positive Tumors: A Meta-Analysis of Published Literatures
por: Zhou, Qiong, et al.
Publicado: (2014)

Benefits of adjuvant treatment including trastuzumab in HER2-positive pT1a-bN0M0 breast cancer: a systematic review and meta-analysis
por: Lee, Hye Yoon, et al.
Publicado: (2020)

Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer
por: Gori, Stefania, et al.
Publicado: (2015)

The survival impact of adjuvant radiotherapy and chemotherapy in patients with non-endometrioid endometrial carcinomas: a PSM-IPTW analysis based on SEER database
por: Hao, Zhimin, et al.
Publicado: (2023)

Her2 positivity and race predict higher mastectomy rates: a SEER database analysis
por: Schwartz, Theresa L., et al.
Publicado: (2015)

Performance of the HPD minimum guidance systeme, pt 1
por: Gérard, J M, et al.
Publicado: (1967)

Extramural extension as indicator for postoperative adjuvant chemotherapy in Stage IIA (pT3N0) colon cancer
por: Akagi, Yoshito, et al.
Publicado: (2013)

Different prognosis by subtype in the early mucinous breast cancer: a SEER population-based analysis
por: Lian, Weibin, et al.
Publicado: (2020)

Survival benefit of adjuvant chemotherapy in elderly patients with stage I triple-negative breast cancer: a cohort study based on the SEER database
por: Zhang, Yuyuan, et al.
Publicado: (2023)

Decision-making of adjuvant therapy in pT1N1M0 gastric cancer: Should radiotherapy be added to chemotherapy? A propensity score-matched analysis
por: Pan, Siwei, et al.
Publicado: (2021)

Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
por: Alexandre, Marie, et al.
Publicado: (2019)

Ribociclib Improves Overall Survival in HR+/HER2– Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
por: Jacobson, Anne
Publicado: (2022)

Timing of Adjuvant Chemoradiation in pT1-3N1-2 or pT4aN1 Esophageal Squamous Cell Carcinoma After R0 Esophagectomy
por: Wu, Leilei, et al.
Publicado: (2020)

Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis
por: Zhang, Jingyi, et al.
Publicado: (2020)

CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
por: Guerrero-Zotano, Ángel, et al.
Publicado: (2023)

Propensity score matching analysis of the prognosis for the rare insular subtype of thyroid cancer based on SEER database
por: Liu, Yan, et al.
Publicado: (2017)

Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer
por: Song, Yan, et al.
Publicado: (2015)

Are We Prepared for the CDK4/6 Revolution With HR+/HER2− Breast Cancers?: The Importance of Patient Adherence to Adjuvant Therapies
por: Azoz, Seyla, et al.
Publicado: (2023)

The role of adjuvant chemotherapy in stage I–III male breast cancer: a SEER-based analysis
por: Li, Wei-Ping, et al.
Publicado: (2020)

The Effectiveness of Postoperative Chemotherapy on pT1bN0 and pT2N0 Gastric Cancer Patients with Risk Factors: An International Dual-Center Analysis
por: Yang, Kun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gklaj5a1mqhanojmf6n14gjf2q